New

Psychiatric Medications Market

2021

Psychiatric Medications Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Classification (First Generation (Typical), and Second Generation (Atypical)); End Use (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, and Others), and Geography

| Report Code: TIPRE00024007 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Psychiatric Medications Market 2028 By Drug Classification, End Use, and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Psychiatric Medications alter behavior, mood, thoughts, or perception. It's a blanket term for various drugs, including prescription drugs and commonly misused drugs. Psychiatric Medications are used to treat various mental health issues when they cause significant hindrances to the body's healthy functioning. Psychiatric Medications usually work by changing or adjusting the number of substantial chemicals in the brain called neurotransmitters. Some psychological issues show improvement when the level of neurotransmitters (dopamine, serotonin, and norepinephrine) increases or decreases. Psychiatric Medications are typically prescribed by a psychiatrist, a psychiatric nurse practitioner (PMHNP), or a primary care physician; in some areas, clinical psychologists may have prescriptive benefits as well.

MARKET SCOPE

The "Global Psychiatric Medications Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Psychiatric medications market with detailed market segmentation by drug classification, application, and geography. The report provides key statistics on the market status of the leading Psychiatric medications market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

    - Based on drug classification, the global Psychiatric medications market is segmented into first generation (typical), second generation (atypical).
    - On the basis of application, the market is segmented into schizophrenia, bipolar disorder, unipolar disorder, dementia, others.

MARKET DYNAMICS
Drivers:

    - Rise in the incidences of Psychotic disorders.
    - Rising concern of government and healthcare organizations on mental health.
    - Rising investment in research and development.

Restraints:

    - The patent expiry and addiction caused due to Psychiatric medications are the major restraining factor for this market.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Psychiatric medications market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

BThe report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Psychiatric medications market in these regions.

IMPACT OF COVID-19 ON PSYCHIATRIC MEDICATIONS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Psychiatric medications market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Psychiatric medications market are anticipated to lucrative growth opportunities in the future with the rising demand for Psychiatric medications in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Psychiatric medications market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

    - Alkermes
    - Eli Lilly and Company
    - Janssen Global Services, LLC (Johnson & Johnson)
    - Allergan (AbbVie Inc.)
    - Pfizer Inc.
    - Mylan N.V.
    - Novartis AG
    - Axsome Therapeutics, Inc.
    - Acadia Pharmaceuticals Inc.
    - Takeda Pharmaceutical Company Limited

The Insight Partner's dediPsychiatric medicationsed research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Psychiatric Medications Market - By Drug Classification
1.3.2 Psychiatric Medications Market - By End Use
1.3.3 Psychiatric Medications Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PSYCHIATRIC MEDICATIONS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PSYCHIATRIC MEDICATIONS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PSYCHIATRIC MEDICATIONS MARKET - GLOBAL MARKET ANALYSIS
6.1. PSYCHIATRIC MEDICATIONS - GLOBAL MARKET OVERVIEW
6.2. PSYCHIATRIC MEDICATIONS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. PSYCHIATRIC MEDICATIONS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASSIFICATION
7.1. OVERVIEW
7.2. DRUG CLASSIFICATION MARKET FORECASTS AND ANALYSIS
7.3. FIRST GENERATION (TYPICAL)
7.3.1. Overview
7.3.2. First Generation (Typical) Market Forecast and Analysis
7.4. SECOND GENERATION (ATYPICAL)
7.4.1. Overview
7.4.2. Second Generation (Atypical) Market Forecast and Analysis
8. PSYCHIATRIC MEDICATIONS MARKET - REVENUE AND FORECASTS TO 2028 - END USE
8.1. OVERVIEW
8.2. END USE MARKET FORECASTS AND ANALYSIS
8.3. SCHIZOPHRENIA
8.3.1. Overview
8.3.2. Schizophrenia Market Forecast and Analysis
8.4. BIPOLAR DISORDER
8.4.1. Overview
8.4.2. Bipolar Disorder Market Forecast and Analysis
8.5. UNIPOLAR DISORDER
8.5.1. Overview
8.5.2. Unipolar Disorder Market Forecast and Analysis
8.6. DEMENTIA
8.6.1. Overview
8.6.2. Dementia Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. PSYCHIATRIC MEDICATIONS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Psychiatric Medications Market Overview
9.1.2 North America Psychiatric Medications Market Forecasts and Analysis
9.1.3 North America Psychiatric Medications Market Forecasts and Analysis - By Drug Classification
9.1.4 North America Psychiatric Medications Market Forecasts and Analysis - By End Use
9.1.5 North America Psychiatric Medications Market Forecasts and Analysis - By Countries
9.1.5.1 United States Psychiatric Medications Market
9.1.5.1.1 United States Psychiatric Medications Market by Drug Classification
9.1.5.1.2 United States Psychiatric Medications Market by End Use
9.1.5.2 Canada Psychiatric Medications Market
9.1.5.2.1 Canada Psychiatric Medications Market by Drug Classification
9.1.5.2.2 Canada Psychiatric Medications Market by End Use
9.1.5.3 Mexico Psychiatric Medications Market
9.1.5.3.1 Mexico Psychiatric Medications Market by Drug Classification
9.1.5.3.2 Mexico Psychiatric Medications Market by End Use
9.2. EUROPE
9.2.1 Europe Psychiatric Medications Market Overview
9.2.2 Europe Psychiatric Medications Market Forecasts and Analysis
9.2.3 Europe Psychiatric Medications Market Forecasts and Analysis - By Drug Classification
9.2.4 Europe Psychiatric Medications Market Forecasts and Analysis - By End Use
9.2.5 Europe Psychiatric Medications Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Psychiatric Medications Market
9.2.5.1.1 Germany Psychiatric Medications Market by Drug Classification
9.2.5.1.2 Germany Psychiatric Medications Market by End Use
9.2.5.2 France Psychiatric Medications Market
9.2.5.2.1 France Psychiatric Medications Market by Drug Classification
9.2.5.2.2 France Psychiatric Medications Market by End Use
9.2.5.3 Italy Psychiatric Medications Market
9.2.5.3.1 Italy Psychiatric Medications Market by Drug Classification
9.2.5.3.2 Italy Psychiatric Medications Market by End Use
9.2.5.4 Spain Psychiatric Medications Market
9.2.5.4.1 Spain Psychiatric Medications Market by Drug Classification
9.2.5.4.2 Spain Psychiatric Medications Market by End Use
9.2.5.5 United Kingdom Psychiatric Medications Market
9.2.5.5.1 United Kingdom Psychiatric Medications Market by Drug Classification
9.2.5.5.2 United Kingdom Psychiatric Medications Market by End Use
9.2.5.6 Rest of Europe Psychiatric Medications Market
9.2.5.6.1 Rest of Europe Psychiatric Medications Market by Drug Classification
9.2.5.6.2 Rest of Europe Psychiatric Medications Market by End Use
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Psychiatric Medications Market Overview
9.3.2 Asia-Pacific Psychiatric Medications Market Forecasts and Analysis
9.3.3 Asia-Pacific Psychiatric Medications Market Forecasts and Analysis - By Drug Classification
9.3.4 Asia-Pacific Psychiatric Medications Market Forecasts and Analysis - By End Use
9.3.5 Asia-Pacific Psychiatric Medications Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Psychiatric Medications Market
9.3.5.1.1 Australia Psychiatric Medications Market by Drug Classification
9.3.5.1.2 Australia Psychiatric Medications Market by End Use
9.3.5.2 China Psychiatric Medications Market
9.3.5.2.1 China Psychiatric Medications Market by Drug Classification
9.3.5.2.2 China Psychiatric Medications Market by End Use
9.3.5.3 India Psychiatric Medications Market
9.3.5.3.1 India Psychiatric Medications Market by Drug Classification
9.3.5.3.2 India Psychiatric Medications Market by End Use
9.3.5.4 Japan Psychiatric Medications Market
9.3.5.4.1 Japan Psychiatric Medications Market by Drug Classification
9.3.5.4.2 Japan Psychiatric Medications Market by End Use
9.3.5.5 South Korea Psychiatric Medications Market
9.3.5.5.1 South Korea Psychiatric Medications Market by Drug Classification
9.3.5.5.2 South Korea Psychiatric Medications Market by End Use
9.3.5.6 Rest of Asia-Pacific Psychiatric Medications Market
9.3.5.6.1 Rest of Asia-Pacific Psychiatric Medications Market by Drug Classification
9.3.5.6.2 Rest of Asia-Pacific Psychiatric Medications Market by End Use
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Psychiatric Medications Market Overview
9.4.2 Middle East and Africa Psychiatric Medications Market Forecasts and Analysis
9.4.3 Middle East and Africa Psychiatric Medications Market Forecasts and Analysis - By Drug Classification
9.4.4 Middle East and Africa Psychiatric Medications Market Forecasts and Analysis - By End Use
9.4.5 Middle East and Africa Psychiatric Medications Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Psychiatric Medications Market
9.4.5.1.1 South Africa Psychiatric Medications Market by Drug Classification
9.4.5.1.2 South Africa Psychiatric Medications Market by End Use
9.4.5.2 Saudi Arabia Psychiatric Medications Market
9.4.5.2.1 Saudi Arabia Psychiatric Medications Market by Drug Classification
9.4.5.2.2 Saudi Arabia Psychiatric Medications Market by End Use
9.4.5.3 U.A.E Psychiatric Medications Market
9.4.5.3.1 U.A.E Psychiatric Medications Market by Drug Classification
9.4.5.3.2 U.A.E Psychiatric Medications Market by End Use
9.4.5.4 Rest of Middle East and Africa Psychiatric Medications Market
9.4.5.4.1 Rest of Middle East and Africa Psychiatric Medications Market by Drug Classification
9.4.5.4.2 Rest of Middle East and Africa Psychiatric Medications Market by End Use
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Psychiatric Medications Market Overview
9.5.2 South and Central America Psychiatric Medications Market Forecasts and Analysis
9.5.3 South and Central America Psychiatric Medications Market Forecasts and Analysis - By Drug Classification
9.5.4 South and Central America Psychiatric Medications Market Forecasts and Analysis - By End Use
9.5.5 South and Central America Psychiatric Medications Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Psychiatric Medications Market
9.5.5.1.1 Brazil Psychiatric Medications Market by Drug Classification
9.5.5.1.2 Brazil Psychiatric Medications Market by End Use
9.5.5.2 Argentina Psychiatric Medications Market
9.5.5.2.1 Argentina Psychiatric Medications Market by Drug Classification
9.5.5.2.2 Argentina Psychiatric Medications Market by End Use
9.5.5.3 Rest of South and Central America Psychiatric Medications Market
9.5.5.3.1 Rest of South and Central America Psychiatric Medications Market by Drug Classification
9.5.5.3.2 Rest of South and Central America Psychiatric Medications Market by End Use
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PSYCHIATRIC MEDICATIONS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. PSYCHIATRIC MEDICATIONS MARKET, KEY COMPANY PROFILES
12.1. ALKERMES
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ELI LILLY AND COMPANY
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. JANSSEN GLOBAL SERVICES, LLC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ALLERGAN
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MYLAN N.V.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NOVARTIS AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. AXSOME THERAPEUTICS, INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ACADIA PHARMACEUTICALS INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Alkermes
2. Eli Lilly and Company
3. Janssen Global Services, LLC (Johnson & Johnson)
4. Allergan (AbbVie Inc.)
5. Pfizer Inc.
6. Mylan N.V.
7. Novartis AG
8. Axsome Therapeutics, Inc.
9. Acadia Pharmaceuticals Inc.
10. Takeda Pharmaceutical Company Limited
11. GlaxoSmithKline plc
12. Otsuka Pharmaceutical Co, Ltd
13. AstraZeneca plc
TIPRE00024007
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.